A detailed history of Vanguard Group Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,365,769 shares of ADGI stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,365,769
Previous 4,295,244 1.64%
Holding current value
$14.5 Million
Previous $14.2 Million 1.64%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
N/A
70,525 Added 1.64%
4,365,769 $14.5 Million
Q2 2024

Aug 13, 2024

BUY
N/A
1,684,042 Added 64.49%
4,295,244 $14.2 Million
Q1 2024

May 10, 2024

BUY
N/A
97,496 Added 3.88%
2,611,202 $8.64 Million
Q4 2023

Feb 14, 2024

BUY
N/A
24,692 Added 0.99%
2,513,706 $8.32 Million
Q2 2023

Aug 14, 2023

SELL
N/A
-210,968 Reduced 7.81%
2,489,014 $8.24 Million
Q1 2023

May 15, 2023

BUY
N/A
8,063 Added 0.3%
2,699,982 $8.94 Million
Q4 2022

Feb 10, 2023

SELL
$3.08 - $4.05 $3.47 Million - $4.57 Million
-1,127,994 Reduced 29.53%
2,691,919 $8.91 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $4.83 $1.54 Million - $2.5 Million
517,645 Added 15.68%
3,819,913 $12 Million
Q2 2022

Aug 12, 2022

SELL
$2.54 - $4.52 $5.14 Million - $9.14 Million
-2,021,858 Reduced 37.98%
3,302,268 $10.8 Million
Q1 2022

May 13, 2022

BUY
$3.81 - $10.77 $14.4 Million - $40.8 Million
3,790,400 Added 247.14%
5,324,126 $24.3 Million
Q4 2021

Feb 14, 2022

SELL
$6.35 - $47.04 $2.4 Million - $17.8 Million
-377,899 Reduced 19.77%
1,533,726 $11.1 Million
Q3 2021

Nov 12, 2021

BUY
$20.88 - $56.08 $39.9 Million - $107 Million
1,911,625 New
1,911,625 $80.7 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.